CABALETTA BIO INC. - COMMON STOCK

Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris

14 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in November

09 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

Cabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer

09 Nov 2021 08:00:04 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update

01 Nov 2021 07:05:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV

01 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021

15 Oct 2021 16:30:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Chardan 5th Annual Genetic Medicines Conference

28 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel

07 Sep 2021 08:00:03 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV

18 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Second Quarter 2021 Financial Results and Provides Business Update

05 Aug 2021 07:30:01 By Nasdaq GlobeNewswire

Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors

28 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Jefferies Healthcare Conference

27 May 2021 08:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates

03 May 2021 07:05:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial

03 May 2021 07:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 20th Annual Needham Healthcare Conference

07 Apr 2021 08:00:02 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

16 Mar 2021 07:30:01 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

23 Feb 2021 08:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

07 Jan 2021 08:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming January Investor Conferences

04 Jan 2021 08:00:00 By Nasdaq GlobeNewswire